FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044705103> ?p ?o ?g. }

• W2044705103 endingPage "130" @default.
• W2044705103 startingPage "121" @default.
• W2044705103 abstract "Like most commercial parenteral emulsions, Intralipid contains the same amount of phospholipids (12 mg/ml) to stabilize 100 or 200 mg of soybean oil (10 or 20% formula, respectively). By centrifugation, 10 or 20% Intralipid was separated into a supernatant, fat particles containing the bulk of triacylglycerols stabilized by a fraction of phospholipids and an infranatant--called mesophase--consisting mainly of phospholipids used in excess as emulsifier. We observed that the initial triacylglycerol/phospholipid ratio of the emulsion (100/12 and 200/12, respectively) determines the size of the triacylglycerol-rich particles (260 and 350 nm) as well as the phospholipid content of the mesophase (6.02 and 4.67 mg/ml). To understand the mechanism of the lipoprotein-X (LPX) accumulation generally reported after intravenous fat infusions, plasma lipid levels and lipoprotein profiles were first compared in the rats after infusion (at a constant rate of 0.5 or 1 ml/h for 43 h) of Intralipid 10 or 20%. For the same intravenous triacylglycerol load (100 mg/h), rats infused with Intralipid 10% at 1 ml/h displayed higher triacylglycerol levels than rats infused with the 20% emulsion at 0.5 ml/h, suggesting that the size of exogenous fat particles modulated the catabolic rate of their triacylglycerols. The plasma levels of LPX varied according to the infusion rate of phospholipids not associated with triacylglycerol-rich particles of the emulsion. Moreover, an apo E and apo B enrichment of plasma and an elevation of the apo B48/apo B100 ratio was always observed after Intralipid infusions. In order to confirm that phospholipids of the mesophase are the main LPX precursors, lipoprotein profiles were then compared in the rats after intravenous infusion, at a constant rate of 1 ml/h, of either the mesophase or a suspension of triacylglycerol-rich particles isolated from Intralipid 20%. As expected, significant LPX amounts were only detected in rats infused with the pure mesophase of the emulsion. It was concluded that products of the lipolysis of exogenous fat particles play only a minor role in the formation of LPX. In fact these abnormal lipoproteins are generated by phospholipids of the mesophase which, like infused liposomes, actively mobilize endogenous free cholesterol. Consequently, in order to be considered as true chylomicron models for safe fat delivery in parenteral nutrition and in order to prevent some detrimental effects on cholesterol metabolism, commercial emulsions should be cleared of phospholipid excess." @default.
• W2044705103 created "2016-06-24" @default.
• W2044705103 creator A5003734999 @default.
• W2044705103 creator A5069359628 @default.
• W2044705103 creator A5090643987 @default.
• W2044705103 date "1990-11-01" @default.
• W2044705103 modified "2023-10-16" @default.
• W2044705103 title "Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: Phospholipids in excess are the main precursors of lipoprotein-X-like particles" @default.
• W2044705103 cites W1574165915 @default.
• W2044705103 cites W1775749144 @default.
• W2044705103 cites W1971590461 @default.
• W2044705103 cites W1978247799 @default.
• W2044705103 cites W1978273961 @default.
• W2044705103 cites W1980484108 @default.
• W2044705103 cites W1981309636 @default.
• W2044705103 cites W1988498959 @default.
• W2044705103 cites W1991945372 @default.
• W2044705103 cites W1998937029 @default.
• W2044705103 cites W2015738326 @default.
• W2044705103 cites W2021811334 @default.
• W2044705103 cites W2024086471 @default.
• W2044705103 cites W2024493540 @default.
• W2044705103 cites W2027987470 @default.
• W2044705103 cites W20309224 @default.
• W2044705103 cites W2033548211 @default.
• W2044705103 cites W2037051261 @default.
• W2044705103 cites W2039537157 @default.
• W2044705103 cites W2053309282 @default.
• W2044705103 cites W2057667069 @default.
• W2044705103 cites W2063725259 @default.
• W2044705103 cites W2065777224 @default.
• W2044705103 cites W2068457362 @default.
• W2044705103 cites W2070872760 @default.
• W2044705103 cites W2077409829 @default.
• W2044705103 cites W2080805159 @default.
• W2044705103 cites W2086342744 @default.
• W2044705103 cites W2090961448 @default.
• W2044705103 cites W2094394242 @default.
• W2044705103 cites W2095098337 @default.
• W2044705103 cites W2100536144 @default.
• W2044705103 cites W2148131794 @default.
• W2044705103 cites W2155602575 @default.
• W2044705103 cites W2170380887 @default.
• W2044705103 cites W2335801071 @default.
• W2044705103 cites W2340386721 @default.
• W2044705103 cites W2410575631 @default.
• W2044705103 cites W2415010164 @default.
• W2044705103 doi "https://doi.org/10.1016/0005-2760(90)90037-x" @default.
• W2044705103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2248969" @default.
• W2044705103 hasPublicationYear "1990" @default.
• W2044705103 type Work @default.
• W2044705103 sameAs 2044705103 @default.
• W2044705103 citedByCount "49" @default.
• W2044705103 countsByYear W20447051032014 @default.
• W2044705103 countsByYear W20447051032015 @default.
• W2044705103 countsByYear W20447051032017 @default.
• W2044705103 countsByYear W20447051032019 @default.
• W2044705103 crossrefType "journal-article" @default.
• W2044705103 hasAuthorship W2044705103A5003734999 @default.
• W2044705103 hasAuthorship W2044705103A5069359628 @default.
• W2044705103 hasAuthorship W2044705103A5090643987 @default.
• W2044705103 hasConcept C126322002 @default.
• W2044705103 hasConcept C138885662 @default.
• W2044705103 hasConcept C147789679 @default.
• W2044705103 hasConcept C185592680 @default.
• W2044705103 hasConcept C187530423 @default.
• W2044705103 hasConcept C2778123984 @default.
• W2044705103 hasConcept C2778163477 @default.
• W2044705103 hasConcept C2778918659 @default.
• W2044705103 hasConcept C2779885280 @default.
• W2044705103 hasConcept C2780072125 @default.
• W2044705103 hasConcept C3020173782 @default.
• W2044705103 hasConcept C40231798 @default.
• W2044705103 hasConcept C41625074 @default.
• W2044705103 hasConcept C41895202 @default.
• W2044705103 hasConcept C43617362 @default.
• W2044705103 hasConcept C55493867 @default.
• W2044705103 hasConcept C62231903 @default.
• W2044705103 hasConcept C62746215 @default.
• W2044705103 hasConcept C71924100 @default.
• W2044705103 hasConcept C7623868 @default.
• W2044705103 hasConcept C78722104 @default.
• W2044705103 hasConcept C96942376 @default.
• W2044705103 hasConceptScore W2044705103C126322002 @default.
• W2044705103 hasConceptScore W2044705103C138885662 @default.
• W2044705103 hasConceptScore W2044705103C147789679 @default.
• W2044705103 hasConceptScore W2044705103C185592680 @default.
• W2044705103 hasConceptScore W2044705103C187530423 @default.
• W2044705103 hasConceptScore W2044705103C2778123984 @default.
• W2044705103 hasConceptScore W2044705103C2778163477 @default.
• W2044705103 hasConceptScore W2044705103C2778918659 @default.
• W2044705103 hasConceptScore W2044705103C2779885280 @default.
• W2044705103 hasConceptScore W2044705103C2780072125 @default.
• W2044705103 hasConceptScore W2044705103C3020173782 @default.
• W2044705103 hasConceptScore W2044705103C40231798 @default.
• W2044705103 hasConceptScore W2044705103C41625074 @default.
• W2044705103 hasConceptScore W2044705103C41895202 @default.
• W2044705103 hasConceptScore W2044705103C43617362 @default.

• next